|
Dr. Mike Mullan is a recognized authority on Alzheimer's disease and related disorders. Dr Mullan is a co-discoverer of the first ever genetic causes of Alzheimer's disease. Consequently, he was a co-inventor on the original patents, covering three mutations in the amyloid precursor protein (APP) gene. He also co-authored the nature and nature genetics paper describing these three genetic errors, He was senior author on two of those manuscripts.〔〔 Dr. Mullan's Alzheimer work resulted in identifying the most widely mutation known as the Swedish Mutation 〔 that is present in familial form. Transgenic Animal models for Alzheimer Disease frequently use the Swedish Mutation to reproduce features of the disease. Dr. Michael Mullan was trained as a physician in England receiving his medical degree from London University. He subsequently gained a PhD in molecular genetics, also from London University. He is an inventor on the patents covering the first ever genetic mutations linked to familial Alzheimer's disease. He has co-authored over 200 papers on Alzheimer's disease and related disorders—on many of which he served as senior author. He has held positions a Professorial Chair and positions as professor of Psychiatry, Neurology, and Pathology. He cofounded the Roskamp Institute, a not-for-profit, stand-alone biomedical research Institute and served in the past as the Director and CEO. The institute is funded by multiple agencies, including the NIH and the Department of Defense. The (Roskamp Institute ) is dedicated to the discovery and development of new treatments for neuropsychiatric disorders including Alzheimer’s disease, traumatic brain injury, Gulf War illness and a variety of related conditions. Dr Mullan serves as the CEO of (Archer Pharmaceuticals ), a for-profit spin-off of the Roskamp Institute. Archer Pharmaceuticals developed a drug which is currently in (phase 3 ) clinical trials in nine countries in Europe. Dr. Michael Mullan along with a team of neuroscientists at the Roskamp Institute invented the Brain Reserve Index, a numerical index that indicates risk of developing Alzheimer's Disease. Dr. Mike Mullan has published over 200 research papers mostly on the causes and potential treatments of Alzheimer’s disease and other central nervous system diseases. Dr. Michael Mullan is currently the CEO and Chairman of the Board for (Rockcreek Pharmaceuticals ). ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Michael Mullan」の詳細全文を読む スポンサード リンク
|